All updated as on -
The Global Epilepsy Market is expected to reach USD 4.80 Billion by 2030, at a CAGR of 8.42% during the forecast period 2022 to 2030.
Seizures occur frequently and unexpectedly in those who suffer from epilepsy, a chronic brain illness. It's one of the most common neurological disorders, affecting people of all ages everywhere. There are currently over 50 million patients living with epilepsy around the world, with 2.4 million new cases detected each year. However, the vast majority of epilepsy cases are idiopathic, which means that their cause is unknown. Drugs, surgery, and implantable devices are used to treat epilepsy symptoms, but there is yet no cure. This highlights the unfulfilled desire for superior cures, which would provide lucrative growth opportunities for existing businesses. Increases in the incidence of both accidental and traumatic brain injuries, as well as the increased likelihood of post-traumatic seizure occurrence in patients with brain injuries, are the key forces driving the growth of the Global Epilepsy Market.
Report Coverage
Global Epilepsy research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Epilepsy report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Epilepsy competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Epilepsy market players and analyses their core competencies in each global market sub-segments.
New trends, such as firms discovering novel treatments for refractory epilepsy and doctors wanting more potent medications, are driving up the amount of R&D spending in the epilepsy market. Reasonable polytherapies and state-of-the-art imaging methods for early diagnosis are driving growth in the market. The widespread adoption of innovative digital healthcare technologies like mHealth and telemedicine is also expected to boost the epilepsy industry. Increases in the incidence of both accidental and traumatic brain injuries, as well as the increased likelihood of post-traumatic seizure occurrence in patients with brain injuries, are the key forces driving the growth of the Global Epilepsy Market. Increased government funding for research into epilepsy medications and therapies has also contributed to the market's expansion. The World Health Organisation (WHO) estimates that more than 50 million people around the world have epilepsy, providing a large potential market. The market is being driven by the rising incidence of traffic accidents, the majority of whose survivors suffer from epilepsy. The increasing proportion of retirees is a key factor in the market's expansion.
The worldwide epilepsy market is divided into the diagnosis market and the treatment market. Due to the availability of effective and inexpensive medications, the treatment sector is expected to maintain its dominant position during the projected period. The segment will expand more when effective medications are approved by regulatory agencies. The diagnostics market, on the other hand, is anticipated to develop at a CAGR of 9.19 percent during the assessment period. The utilisation of numerous imaging tests and blood testing to locate the issue early is expected to speed up segment growth by a factor of 10.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Epilepsy market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Epilepsy market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Epilepsy market based on the below-mentioned segments:
Global Epilepsy Market, By Condition
Global Epilepsy market, By Diagnosis and Treatment
Global Epilepsy Market, By End User
Global Epilepsy market, Regional Analysis
Seizures occur frequently and unexpectedly in those who suffer from epilepsy, a chronic brain illness. It's one of the most common neurological disorders, affecting people of all ages everywhere. There are currently over 50 million patients living with epilepsy around the world, with 2.4 million new cases detected each year. However, the vast majority of epilepsy cases are idiopathic, which means that their cause is unknown. Drugs, surgery, and implantable devices are used to treat epilepsy symptoms, but there is yet no cure. This highlights the unfulfilled desire for superior cures, which would provide lucrative growth opportunities for existing businesses. Increases in the incidence of both accidental and traumatic brain injuries, as well as the increased likelihood of post-traumatic seizure occurrence in patients with brain injuries, are the key forces driving the growth of the Global Epilepsy Market.
Report Coverage
Global Epilepsy research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Epilepsy report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Epilepsy competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Epilepsy market players and analyses their core competencies in each global market sub-segments.
New trends, such as firms discovering novel treatments for refractory epilepsy and doctors wanting more potent medications, are driving up the amount of R&D spending in the epilepsy market. Reasonable polytherapies and state-of-the-art imaging methods for early diagnosis are driving growth in the market. The widespread adoption of innovative digital healthcare technologies like mHealth and telemedicine is also expected to boost the epilepsy industry. Increases in the incidence of both accidental and traumatic brain injuries, as well as the increased likelihood of post-traumatic seizure occurrence in patients with brain injuries, are the key forces driving the growth of the Global Epilepsy Market. Increased government funding for research into epilepsy medications and therapies has also contributed to the market's expansion. The World Health Organisation (WHO) estimates that more than 50 million people around the world have epilepsy, providing a large potential market. The market is being driven by the rising incidence of traffic accidents, the majority of whose survivors suffer from epilepsy. The increasing proportion of retirees is a key factor in the market's expansion.
The worldwide epilepsy market is divided into the diagnosis market and the treatment market. Due to the availability of effective and inexpensive medications, the treatment sector is expected to maintain its dominant position during the projected period. The segment will expand more when effective medications are approved by regulatory agencies. The diagnostics market, on the other hand, is anticipated to develop at a CAGR of 9.19 percent during the assessment period. The utilisation of numerous imaging tests and blood testing to locate the issue early is expected to speed up segment growth by a factor of 10.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | LivaNova PLC, GlaxoSmithKline plc., Eisai Co., Ltd., Pfizer Inc., Medtronic, UCB S.A., NeuroPace, Inc., GW Pharmaceuticals plc., Novartis AG, Abbott, Teva Pharmaceutical Industries Ltd, Sunovion Pharmaceuticals Inc., Sumitomo Dainippon Pharma Co. Ltd., Bausch & Lomb Incorporated, Sanofi, Takeda Pharmaceutical Company Limited., Marinus Pharmaceuticals Inc., Upsher-Smith Laboratories LLC., SK BIOPHARMACEUTICALS, Vertex Pharmaceuticals Incorporated, ESTEVE., Zogenix, Supernus Pharmaceuticals Inc, DAIICHI SANKYO COMPANY, LIMITED |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Epilepsy Market from 2021 to 2030.
- Market Forecast for Epilepsy Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Epilepsy competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Epilepsy
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Epilepsy market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Epilepsy market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
- LivaNova PLC
- GlaxoSmithKline plc.
- Eisai Co., Ltd.
- Pfizer Inc.
- Medtronic
- UCB S.A.
- NeuroPace, Inc.
- GW Pharmaceuticals plc.
- Novartis AG
- Abbott
- Teva Pharmaceutical Industries Ltd
- Sunovion Pharmaceuticals Inc.
- Sumitomo Dainippon Pharma Co. Ltd.
- Bausch & Lomb Incorporated
- Sanofi
- Takeda Pharmaceutical Company Limited.
- Marinus Pharmaceuticals Inc.
- Upsher-Smith Laboratories LLC.
- SK BIOPHARMACEUTICALS
- Vertex Pharmaceuticals Incorporated
- ESTEVE
- Zogenix
- Supernus Pharmaceuticals Inc
- DAIICHI SANKYO COMPANY, LIMITED
Primary Target Market
- Market Players of Epilepsy
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Epilepsy market based on the below-mentioned segments:
Global Epilepsy Market, By Condition
- Drug-resistant/intractable epilepsy
- Others
Global Epilepsy market, By Diagnosis and Treatment
- Diagnosis
- Treatment
Global Epilepsy Market, By End User
- Diagnosis
- Treatment
Global Epilepsy market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive epilepsy market market research and competitor analysis for your business to help you develop more profound insights into the epilepsy market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the epilepsy market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.